18 studies found for:    Open Studies | "Hemorrhagic Fever, Ebola"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemorrhagic Fever, Ebola"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
2 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
3 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
4 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
5 Recruiting Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Condition: Ebola Virus
Interventions: Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Drug: Placebo
6 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
7 Not yet recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
8 Recruiting Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: HPIV3-EbovZ GP Vaccine
9 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
10 Recruiting Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Condition: Ebola Virus Infection
Interventions: Drug: ZMApp;   Other: Treatment A
11 Recruiting A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Conditions: Filovirus Infections;   Ebola Virus Infection
Interventions: Drug: BCX4430;   Drug: Placebo
12 Recruiting Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Menveo;   Biological: Placebo
13 Recruiting A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
Condition: Healthy
Interventions: Biological: MVA-BN-Filo;   Biological: Ad26.ZEBOV;   Biological: Placebo
14 Not yet recruiting A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Condition: Virus Diseases
Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A);   Drug: Placebo
15 Recruiting A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
Condition: Virus Diseases
Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A);   Biological: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
16 Recruiting A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV 5*10^10 viral particles (vp);   Biological: Ad26.ZEBOV 2*10^10 (vp);   Biological: Ad26.ZEBOV 0.8*10^10 (vp);   Biological: MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.];   Biological: MVA‐BN‐Filo 5*10^7 Inf. U.;   Biological: Placebo
17 Recruiting A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV‐Batch #1;   Biological: Ad26.ZEBOV‐Batch #2;   Biological: Ad26.ZEBOV‐Batch #3;   Biological: MVA‐BN‐Filo;   Biological: Placebo
18 Recruiting Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers
Condition: Healthy
Intervention: Drug: ZMAPP

Indicates status has not been verified in more than two years